Identifying patients at risk of relapse of (metastatic) colorectal cancer with targeted imaging
META-DETECT will develop a multi-target imaging agent to diagnose, stage and determine the risk of relapse in colorectal cancer (CRC). The novel imaging agent will combine llama VHH antibody fragments with a nanoparticle that can be visualized with numerous imaging instruments rendering an unparalleled sensitivity and specificity. It will be able to accurately localize and characterize tumours, and predict the risk for CRC relapse, which will significantly improve the chance of survival.
2 113 950.00€
Medical devices technology (instrumentation, medical imaging, radiology)